- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patie...
- Marked sales of KRW 272.2 billion and operating profit of KRW 26.8 billion - Reported record-high...
* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnolog...
We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers s...
- From Last February to mid-March, NDA has been submitted to each country sequentially - Daewoong ...
SEOUL, South Korea, Feb. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) announced the ...
SEOUL, South Korea, Feb. 21, 2022 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today...
* Recorded operating profit KRW 88.9 billion and net profit KRW 31.6 billion in 2021 with the out...
SEOUL, South Korea, Jan. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) has confirmed ...
* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10...
* Advancement of Nabota and prescriptions... KRW 290.6B sales and KRW 22.7B operating income * ...
* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating ...
* CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot techno...
SEOUL, South Korea, Aug. 19, 2021 /PRNewswire/ -- Daewoong Pharmaceutical and Hanall Biopharma ofSo...
* Q2'21 sales of KRW 23.4 billion increased 4% from the same period last year * Q2'21 operating ...
- Improvement of symptoms such as cough and dyspnea in mild patients over age 50 was reported to be...
SEOUL, South Korea, June 1, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon) announce...
* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage ...
* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage *...
* OP. income exceeded 20 billion won due to successful export of Fexuprazan and sales recovery ...